Purchasing Tips: What Does Glucagon Do in Peptide Therapy?
Abstract: Glucagon in peptide therapy primarily elevates blood glucose by activating hepatic glycogenolysis, contrasting with insulin’s effects. Current market trends show a 12.3% CAGR for therapeutic peptides (2023–2030), driven by diabetes and metabolic disorder applications. Brand comparisons reveal Novo Nordisk’s glucagon (GlucaGen) leads in purity (>99%) and stability, while generic alternatives offer cost savings but lower batch consistency. Key technical advantages include rapid onset (5–15 min) and reversible action; drawbacks involve short half-life (3–6 min) requiring reconstitution. Product parameters vary: 1 mg/vial standard, with pH 2.5–3.5 for solubility. Industry data indicates 78% of clinics prioritize GMP-certified suppliers. Logistics require cold chain (2–8°C) and lyophilized storage to maintain potency. Selecting GMP-compliant, third-party-tested glucagon ensures efficacy and safety in peptide therapy.